A Phase 1b Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Golimumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 17 Feb 2021 Status changed from recruiting to completed.
- 21 Jan 2020 Planned End Date changed from 21 Feb 2021 to 20 Aug 2021.
- 11 Nov 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.